Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA in Subjects With Exudative Age-Related Macular Degeneration

Next Previous
X
Search
Trial Profile

A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA in Subjects With Exudative Age-Related Macular Degeneration

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brolucizumab (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Alcon

    • Most Recent Events

    • 01 Sep 2017 Results assessing the efficacy and safety of brolucizumab with aflibercept to treat neovascular age-related macular degeneration (AMD), were published in the Ophthalmology.
    • 27 Feb 2015 Results presented in 38th Annual Macula Society Meeting in Scottsdale, Arizona, as per Novartis media release.
    • 27 Feb 2015 Primary endpoint has been met. (Best corrected visual acuity (Change from baseline in best-corrected visual acuity.), as per Novartis media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top